-
Tasly's subsidiary bezafibrate sustained-release tablets and temozolomide for injection obtained drug registration certificates
Time of Update: 2021-11-04
On October 21, Tasly issued an announcement stating that its subsidiaries, bezafibrate sustained-release tablets and temozolomide for injection, have obtained drug registration certificates .
Sustained-release bezafibrate tablets are used to treat adult hypertriglyceridemia and mixed hyperlipidemia .
-
A quick look at the news about foreign "medicine" this month
Time of Update: 2021-11-04
A quick overview of key foreign drug news this month: Roche T drug was approved to treat early lung cancer; FDA approved Merck K drug combined with chemotherapy for first-line treatment of cervical cancer; AstraZeneca Imfinzi combined with tremelimumab to treat liver cancer phase 3 clinical end; Eli Lilly Verzenio was awarded FDA approved the treatment of early breast cancer .
-
With the general rise in the performance of the third quarterly reports of medical companies, they are still facing severe performance tests
Time of Update: 2021-11-04
613 billion yuan and net profit attributable to shareholders of listed companies of 2.
It is worth noting that since its listing in October 2018, Mindray Medical's single-quarter net profit growth rate has continued to remain above 20% .
-
Osaikon's subsidiary zoledronic acid concentrated solution for injection obtained the notification of acceptance of the listing application
Time of Update: 2021-11-04
On October 21, Osaikang issued an announcement stating that its wholly-owned subsidiary, Jiangsu Osaikang, had recently received the "Notice of Acceptance" for the marketing application for concentrated zoledronic acid solution for injection issued by the National Medical Products Administration .
-
The tuberculosis war never stopped: an overview of multidrug-resistant tuberculosis drugs
Time of Update: 2021-11-04
On November 23, 2016, the drug was approved by the China National Medical Products Administration NMPA (trade name Snair) for the treatment of multi-drug-resistant tuberculosis .
-
Analysis of the layout of Chinese innovative drugs at home and abroad: Do not all innovative drugs have a future?
Time of Update: 2021-11-04
Analysis of the overall situation of China's pharmaceutical industryOn October 8, 2021, Evive Biotech, a holding subsidiary of Evive Biotech, announced that the European Medicines Agency (EMA) has officially accepted Evive Ryzneuta™ for the treatment of chemotherapy-induced neutropenia (CIN).
-
Beihai Kangcheng's clinical trial application for the treatment of Gaucher's disease CAN103 new drug approved in China
Time of Update: 2021-11-04
(hereinafter referred to as "Beihai Kangcheng") is a leading rare disease biopharmaceutical company based in China and has been committed to For the research, development and commercialization of innovative therapies .
-
CStone Pharmaceuticals announced that the clinical trial application of lolatinib for ROS1-positive advanced non-small cell lung cancer in China has been accepted by the China National Medical Products Administration
Time of Update: 2021-11-04
Suzhou, China, October 20, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, It was announced today that the clinical trial application (IND) of lorlatinib (lorlatinib, formerly known as loratinib) for ROS1-positive advanced non-small cell lung cancer (NSCLC) has been accepted by the National Medical Products Administration (NMPA) of China .
-
Biotech BAT7104 Injection Obtained Clinical Trial Approval Notice
Time of Update: 2021-11-04
On October 19, Biotech issued an announcement stating that the company had recently received the "Clinical Trial Approval Notice" for the company's drug BAT7104 injection, which was approved and issued by the National Medical Products Administration .
-
Pharmaceutical stocks are showing signs of rebound, and many sub-sectors are optimistic
Time of Update: 2021-11-04
Implemented in the direction of allocation: focus on the rhythm of core assets, focus on external demand and focus on global international competitive advantages (CDMO, the global new crown vaccine & therapeutic drug industry chain, injection exports, and some internationalized equipment); the sharp decline is looking for early pessimistic expectations Suppressed health consumption upgrade (consumer medical care, medical services, etc.
-
Xiao Ling, director of Jinling Pharmaceutical, resigns
Time of Update: 2021-11-04
On October 20, Jinling Pharmaceutical issued an announcement stating that the board of directors had recently received a resignation report from director Ms.
-
Improved new drugs become a new "blue ocean", and there will be three major trends in future development
Time of Update: 2021-11-04
Relying on the above advantages, in recent years, as the development of new targets has become more difficult and the competition for generic drugs has become increasingly fierce, for pharmaceutical companies that cannot afford the huge cost of original innovation, improved new drugs are becoming a new hot spot for their research and development .
-
Under the heavy blow, how can the pharmaceutical industry survive the "cold winter"?
Time of Update: 2021-11-04
" From the overall trend, the pharmaceutical industry is reshuffled in It is inevitable that a large number of pharmaceutical agents will be eliminated, and pharmaceutical representatives who continue to remain in the industry will only develop in a more professional direction.
In the future, pharmaceutical representatives will not disappear.
-
After one year of centralized procurement, the average price of drugs in the major provinces of medicine has been reduced by 44.3%
Time of Update: 2021-11-04
The industry believes that as the relevant departments of Hainan Province continue to rely on the new model of pharmaceutical recruitment and price supervision, and related regulatory policy documents to help the development of the pharmaceutical industry, they will further correct the unhealthy trends in the Hainan pharmaceutical purchase and sales field, and standardize and improve Hainan’s pharmaceutical and pharmaceutical products.
-
Aosaikang's subsidiary Polymyxin E Methanesulfonate Sodium for Injection Obtained Drug Registration Approval
Time of Update: 2021-11-04
Polymyxin E sodium methanesulfonate for injection has become the last line of defense for multi-drug-resistant Gram-negative bacterial infections that are ineffective in the treatment of antibiotics such as β-lactams, aminoglycosides or quinolones .
-
National procurement has landed, the two provinces do not engage in "one size fits all", and the allocation ratio of unselected varieties in Shanghai is about 20%
Time of Update: 2021-11-04
At present, 25 provinces and cities have clarified the official implementation time of the fifth batch of national procurement: Xinjiang: September 15, 2021 Tianjin: September 20, 2021 Hunan: October
-
17 types of proprietary Chinese medicines have been purchased in quantity and started to be reported!
Time of Update: 2021-11-04
According to the historical procurement data filled by the medical institutions in the alliance region, among the products of the same product group, the same company, and different dosage forms and specifications, the product with the largest purchase amount is used as the representative product for quotation, and the smallest retail package (such as: box) is used as the price.
-
Nanjing Zhengda Tianqing's first imitation anti-tumor drug has been evaluated as the leader
Time of Update: 2021-11-04
Figure 1: The latest approved products of Nanjing Chia Tai TianqingSource: CDE official websiteFigure 2: Sales of raltitrexed for injection (unit: ten thousand yuan)Source: Mi Nei. com, China's public medical institutions terminal competition patternRaltitrexed can specifically act on thymidylate synthase, thereby inhibiting cell DNA synthesis.
-
Teyi Pharmaceutical's compound sulfamethoxazole tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-11-04
Compound sulfamethoxazole tablets are sulfa antibacterial drugs, which are a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP).
The drug is mainly used to prevent or treat infections caused by sensitive strains .
-
Novo Nordisk's GLP-1+GIP combination treatment of type 2 diabetes new drug clinical application approved
Time of Update: 2021-11-04
Article source: Medical Rubik's Cube InfoAuthor: SunshineRecently, CDE official website showed that Novo Nordisk NNC0480-0389 injection combined with smeglutide injection to assist diet and exercise to improve the blood sugar control of patients with type 2 diabetes has been approved for clinical application of a new drug .
